USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Mallinckrodt Pharmaceuticals Ireland Limited

USPTO PatentsView assignee record - 45 granted patents across 19 technology areas, active 2021–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

11.7

Avg claims per patent

5-year filing velocity

The verdict

Mallinckrodt holds 45 US patents across 19 technology areas, rank #7,299 of 50,000 tracked assignees.

#7,299
of 50,000 US assignees by volume: Top 7%
by Innovation Score (55.7/100): 11.7
avg claims per patent

Portfolio overview

Mallinckrodt Pharmaceuticals Ireland Limited has been granted 45 US utility patents between 2021 and 2025, placing Mallinckrodt Pharmaceuticals Ireland Limited at rank #7,299 across all assignees tracked by PlainPatent. This portfolio spans 19 distinct Cooperative Patent Classification (CPC) subclasses, averaging 11.7 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a Foreign Corporation, Mallinckrodt Pharmaceuticals Ireland Limited is one of the more focused assignees in the PatentsView dataset. By volume, Mallinckrodt sits between Medimop Medical Projects Ltd. (45 patents, rank #7,295) and Moogsoft Inc. (45 patents, rank #7,303) - the closest US assignees by grant volume. The composite Innovation Score of 55.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2021 through 2025, with 45 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Mallinckrodt Pharmaceuticals Ireland Limited's 11.7 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 19 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Mallinckrodt Pharmaceuticals Ireland Limited against peers pursuing similar technology classes.

Medimop Medical P…

45
Movea

45
MY JOB Matcher

45
Magna Powertrain…

45
Mapquest

45
Mexichem Amanco H…

45
Microvast Power S…

45
Moogsoft

45
Mallinckrodt Phar… ◀

45

What this shows Mallinckrodt holds 45 patents at rank #7,299, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Mallinckrodt

By rank, the assignees closest to #7,299 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media INTO)

Other assignees with the most granted patents in Mallinckrodt's primary technology class.

Mallinckrodt's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

56 Top 7% higher than 93% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Mallinckrodt Pharmaceuticals Ireland Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	7	15.6%
2022	11	24.4%
2023	6	13.3%
2024	7	15.6%
2025	14	31.1%

Which technologies does Mallinckrodt Pharmaceuticals Ireland Limited patent most?

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 30

G01F - MEASURING VOLUME, VOLUME FLOW, MASS FLOW OR LIQUID LEVEL; METERING BY VOLUME 11

F17C - VESSELS FOR CONTAINING OR STORING COMPRESSED, LIQUEFIED OR SOLIDIFIED GASES; FIXED-CAPACITY GAS-HOLDERS; FILLING VESSELS WITH, OR DISCHARGING FROM VESSELS, COMPRESSED, LIQUEFIED, OR SOLIDIFIED GASES 7

B63C - LAUNCHING, HAULING-OUT, OR DRY-DOCKING OF VESSELS; LIFE-SAVING IN WATER; EQUIPMENT FOR DWELLING OR WORKING UNDER WATER; MEANS FOR SALVAGING OR SEARCHING FOR UNDERWATER OBJECTS 7

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 7

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 6

B01D - SEPARATION 6

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 5

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 5

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 5

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 3

C01B - NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; ; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C 3

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 3

B01J - CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

Top 15 of 19 technology areas

Patent Moat Analysis

Portfolio Volume Light

Tech Breadth Focused

Claim Depth Simple

Where it ranks

Overall rank by patents

#7,299

Across all tracked assignees

Innovation Score

55.7 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Mallinckrodt Pharmaceuticals Ireland Limited hold?

Mallinckrodt Pharmaceuticals Ireland Limited holds 45 US granted patents filed between 2021 and 2025, spanning 19 technology areas.

What is Mallinckrodt Pharmaceuticals Ireland Limited's Innovation Score?

Mallinckrodt Pharmaceuticals Ireland Limited has an Innovation Score of 55.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Mallinckrodt Pharmaceuticals Ireland Limited focus on?

Mallinckrodt Pharmaceuticals Ireland Limited's top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 30 patents. The company has filed patents in 19 CPC subclasses total.

Is Mallinckrodt Pharmaceuticals Ireland Limited's patent filing rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Mallinckrodt Pharmaceuticals Ireland Limited.

What does claim depth mean for Mallinckrodt Pharmaceuticals Ireland Limited's patents?

Mallinckrodt Pharmaceuticals Ireland Limited's patents average 11.7 claims each. This is relatively simple claim structure, typical for focused inventions.

How is the Mallinckrodt Pharmaceuticals Ireland Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Mallinckrodt's 45 grants land it in the top 7% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Mallinckrodt ranks #7,299 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61M - see who else leads that technology area. A61M leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.